nkx019
Generic: Belacabnagene Franleucel
nkx019: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nkarta, Inc. (NKTX) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases
FDA Decisions
FDA_MeetingFDA cleared IND application to evaluate NKX019 for the treatment of systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.(NKTX)
Frequently asked questions
Who is developing nkx019?
nkx019 is being developed by Nkarta, Inc..
How many clinical trials involve nkx019?
BioSniper tracks 1 clinical trial involving nkx019.
What is nkx019's latest FDA decision?
The most recent tracked FDA decision for nkx019 is FDA_Meeting for FDA cleared IND application to evaluate NKX019 for the treatment of systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis., dated June 27, 2024.
Get deeper analysis on nkx019
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis